Bukwang Pharmaceutical IND says CP-012 trial costs to continue until next year, growth to continue led by Latuda
Predicted impact: Low
Trial cost timing and Latuda growth outlook; no quantified financial impact given.
Bukwang Pharmaceutical IND부광약품
003000 · KOSPI · ₩003000 · 부광약품
₩3,750▼ ₩5 (0.13%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −3.10%
- Market cap
- ₩370B
- Enterprise value
- ₩346B
- P/E
- 42.1×
- P/B
- 1.1×
- Dividend yield
- 3.3%
- ROE
- 2.6%
- Net margin
- 4.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−62.1% from the high
₩3,580Today: ₩3,730 – ₩3,795₩9,890
Returns
- 1W−3.6%
- 1M−6.5%
- 3M+2.3%
- 6M−43.0%
- YTD−0.9%
- 1Y−3.1%
- Volume today
- 217,766
- 0.6× the 20-day average
- Traded today
- ₩818M
- Listed shares
- 98,664,671
- EPS (12 months)
- ₩89
- Earnings yield 2.4%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumFlat-4.6% over the last month; the price is below its 20-day average.
- News impactSome5 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Bukwang Pharmaceutical IND stock overview
Bukwang Pharmaceutical IND (부광약품, KRX: 003000) is listed on KOSPI, in the Biotech & Pharma sector. The company was founded in 1960 to manufacture and sell pharmaceuticals. Its shares closed at ₩3,750 on Oct 28, 2026, down 0.13% on the day, giving it a market value of ₩370B.
Key facts
- Market cap
- ₩370B
- Sector
- Biotech & Pharma
- Latest price change
- −0.13%
- As of
- Oct 28, 2026
- Main business
- The company was founded in 1960 to manufacture and sell pharmaceuticals.
Quick answers about Bukwang Pharmaceutical IND
- What does Bukwang Pharmaceutical IND do?
- The company was founded in 1960 to manufacture and sell pharmaceuticals. Its main businesses are prescription drugs, health functional foods, and other quasi-drugs, with products including Dexid, Ferroba, Regalon, Thioctacid, Latuda, and Thyroid. 7 billion won in the latest year, with growth driven by its CNS product lineup and RNA technology revenue, and it also conducts pharmaceutical research and development.
- What is the market cap of Bukwang Pharmaceutical IND?
- The market capitalisation of Bukwang Pharmaceutical IND was ₩370B at the close on Oct 28, 2026.
- Who are the largest shareholders of Bukwang Pharmaceutical IND?
- According to the latest official filings, the largest reported holders are OCI Holdings (17.68%, as of Jul 24, 2025); Kim Dong-yeon (11.13%, as of Jul 1, 2025); Jung Chang-soo (8.84%, as of Jul 1, 2025).
- When is the next earnings report from Bukwang Pharmaceutical IND?
- Korean companies rarely announce results dates in advance. Based on when Bukwang Pharmaceutical IND filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Bukwang Pharmaceutical IND?
- Yes. The National Pension Service held 0.68% of Bukwang Pharmaceutical IND shares as of Dec 31, 2025.
Company profile
The company was founded in 1960 to manufacture and sell pharmaceuticals. Its main businesses are prescription drugs, health functional foods, and other quasi-drugs, with products including Dexid, Ferroba, Regalon, Thioctacid, Latuda, and Thyroid. Consolidated revenue reached 200.7 billion won in the latest year, with growth driven by its CNS product lineup and RNA technology revenue, and it also conducts pharmaceutical research and development.
Written by AI from the company's latest annual report.
- Korean name
- 부광약품
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- Business group
- OCI
- CEO
- 이제영
- Founded
- Oct 1960
- Listed
- Aug 1988
- Listed shares
- 98,664,671
- Fiscal year ends
- Month 12
- Website
- www.bukwang.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Bukwang Pharmaceutical IND Q3 Operating Profit at ₩2.2B, Up 120% YoY
Predicted impact: Low
Q3 operating profit of 2.2 billion won, up 120%, but tiny versus revenue and market value.
[Today's IR] Woori Financial Group, Hana Financial Group, Bukwang Pharmaceutical IND and others
Woori Financial Group₩29,900▲3.64%Hana Financial Group₩115,300▲1.77%Bukwang Pharmaceutical IND₩3,750▼0.13%
Predicted impact: Low
Recent filings
See all- Preliminary earnings (consolidated)Oct 23, 2026
- Investor relations (IR) eventOct 15, 2026
- Decision Regarding Rehabilitation and Bankruptcy Procedures of Invested CompanyAug 31, 2026
- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 28, 2026
- Acquisition of property, plant and equipmentAug 26, 2026
Titles in Korean until English translations are added.
Also known as: Bukwang Pharmaceutical IND / 부광약품 / 003000 / KRX:003000
Source: KRX statistical information